VAD regimen, combining vincristine, doxorubicin, and dexamethasone was given to 6 previously untreated and 4 treated patients with multiple myeloma. The response rate was obtained in 67% of previously untreated patients and in 50% of previously treated patients. In responders, a rapid improvement of clinical symptoms accompanied with a significant decrease in M-protein was observed. Patients with response to VAD therapy were received melphalan and prednisolone as maintenance. Response duration ranged between 4 months and 38 months. The infectious episodes were occurred in 36.8% patients but none of these was serious. The present results suggest that VAD regimen is useful as primary treatment for multiple myeloma when rapid control of disease is necessary.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bilateral Wilms tumors: Treatment results from a single center.
Turk J Pediatr
January 2020
Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Aydın B, Akyüz C, Yalçın B, Ekinci S, Oğuz B, Akçören Z, Yıldız F, Varan A, Kurucu N, Büyükpamukçu M, Kutluk T. Bilateral Wilms tumors: Treatment results from a single center. Turk J Pediatr 2019; 61: 44-51.
View Article and Find Full Text PDFThe VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.
Biomed Res Int
March 2019
Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
The VAD (vincristine-doxorubicin-dexamethasone) regimen has been used for decades to treat multiple myeloma (MM). Based on reports that vascular endothelial growth factor- (VEGF-) mediated angiogenesis is critical for MM pathogenesis, the antiangiogenic compound thalidomide has been added to VAD (T-VAD). However, it remains unclear whether T-VAD is more efficacious than VAD for serum VEGF reduction or if the difference influences clinical outcome.
View Article and Find Full Text PDF[Efficacy and safety of DVD and VAD regimens in patients with newly diagnosed multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi
June 2017
Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
[Effect of CIK Cells Comined with VAD on Short Prognosis of Patients with Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2017
Department of Hematology and Oncology, The Second People's Hospital of Nanyang, Nanyang 473000, Henan Province, China.
Objective: To explore the effect of CIK cells comined with VAD regimen on prognosis of patients with multiple myeloma(MM).
Methods: Forty-six cases of MM were divided into observation group and control group, the control group was treated by VAD and the observation group was treated by CIK cells comined with VAD. The prognosis between 2 groups was compared.
[Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2017
Department of Hematology & Oncology, Nanyang Municipal Second People's Hospital, Nanyang 473000, Henan Province, China. E-mail:
Objective: To explore the clinical effects of T-VD regimen (bortezomib+dexamethasone+thalidomid) and T-VAD regimen (vincristine+adriamycin+dexamethasone+thalidomide) on the patients with multiple myeloma(MM).
Methods: Thirty cases of MM treated by T-VD(T-VD group) and 30 cases of MM treated by T-VAD(T-VAD group) from April 2010 to April 2012 were included in this study. The clinical effects and long-term survival were compared betwwen these 2 groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!